Ligand Pharmaceuticals Incorporated (LGND) Q2 2023 Earnings Results

Ligand Pharmaceuticals Beats on EPS, Stock Up 1.25%

Ligand Pharmaceuticals reported a strong earnings surprise with an EPS of $1.42, significantly above expectations. This positive result led to a 1.25% increase in the stock price. However, the lack of revenue figures and guidance may leave investors cautious about future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.42	N/A	+268.83%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a positive outlook regarding their earnings performance. However, they did not offer specific guidance for future quarters.

Management expressed satisfaction with the EPS performance despite not providing revenue figures.

They highlighted ongoing strategic initiatives aimed at future growth.

Ligand Pharmaceuticals Beats on EPS, Stock Up 1.25%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Beats on EPS, Stock Up 1.25%

Key numbers

Management commentary